Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
    Home > Research & Grants > Grants Program > Research Grants > Research Grants Awarded > Abstract

    Research Grants Awarded

    Multiplexed Biomarkers for Early Detection and Remission Monitoring of Breast Cancer

    Study Section:
    Detection, Diagnosis and Prognosis

    Scientific Abstract:
    Breast cancer is one of the most common causes of cancer related deaths in women. Despite the effective treatment strategy, large numbers of women succumb each year to breast cancer. Efficient early diagnostic could substantially increase cure rate. However, the current detection modality, screening mammography, still cannot detect all breast cancers and does not identify breast cancers at the ideal earliest stage. There is a critical need to develop new methods to identify early stage disease. Such methods could also be useful for remission monitoring. We have utilized novel LabMAP technology that allows for simultaneous evaluation of multiple biomarkers in one sample, to demonstrate that a combined panel consisting of several cancer-associated biomarkers provides 100% sensitivity and specificity for discrimination of women with breast cancer from healthy women and women with benign breast lesions in a case/control setting. Our goal is to develop a reliable serum-based assay for early detection and prognosis of breast cancer. The following Specific Aims are proposed: 1. Validate/optimize the preliminary multimarker panel in retrospective and prospective longitudinal studies of women at high risk of developing breast cancer; 2 . Validate the utility of this multimarker panel for monitoring of remission; and 3. Identify the multimarker panel effective for in vivo measuring of therapeutic response . At the conclusion of this study, we expect to develop a reliable blood-based assay for the early detection and monitoring of remission in breast cancer, as well as to identify biomarker combination predictive of therapy response.

    Lay Abstract:
    Breast cancer is one of the most common causes of cancer related deaths in women. Despite the effective treatment strategy, large numbers of women succumb each year to breast cancer. Efficient early diagnostic could substantially increase cure rate. However, the current detection modality, screening mammography, still cannot detect all breast cancers and does not identify breast cancers at the ideal earliest stage. There is a critical need to develop new methods to identify early stage disease. Such methods could also be useful for remission monitoring. We have developed a novel multimarker assay that allows for highly accurate discrimination of women with breast cancer from healthy women and women with benign breast lesions. Our goal is to develop a reliable serum-based assay for early detection and prognosis of breast cancer. We propose to: 1. Evaluate the multimarker assay in large population of women at high risk for developing breast cancer to determine whether it is advantageous as compared with mammography; 2 . Validate the utility of this assay for monitoring breast cancer patients in remission; and 3. Develop a multimarkers assay that is effective for measuring of therapeutic response . At the conclusion of this study, we expect to develop a reliable blood-based assay for the early detection and monitoring of remission in breast cancer, as well as to identify biomarker combination predictive of therapy response.